A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers

Neuropsychopharmacology

Volumn 32, Issue 8, 2007, Pages 1678-1686

  Zack, Martin ^a,b,c   Poulos, Constantine X ^c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2; Dopamine; Gambling; Haloperidol; Priming; Reward

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; HUMAN; MALE; MODULATION; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; REINFORCEMENT; REWARD; SELF REPORT;

ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; GAMBLING; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; REWARD; SEMANTICS;

EID: 34447513956     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301295     Document Type: Article

References (49)

1. Amit Z, Smith BR (1992). Remoxipride, a specific D2 dopamine antagonist: an examination of its self-administration liability and its effects on d-amphetamine self-administration. Pharmacol Biochem Behav 41: 259-261.
2. Arndt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101.
3. Bari AA, Pierce RC (2005). D1-like and D2 dopamine receptor antagonists administered into the shell subregion of the rat nucleus accumbens decrease cocaine, but not food, reinforcement. Neuroscience 135: 959-968.
4. Beaudoin CM, Cox BJ (1999). Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire. Can J Psychiatry 44: 483-487.
5. Beck AT, Beck RW (1972). Screening depressed patients in family practice. A rapid technique. Postgrad Med 52: 81-85.
6. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE (1995). Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5: 121-141.
7. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG et al (1996). The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89: 396-400.
8. Brauer LH, de Wit H (1996). Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 39: 26-32.
9. Brauer LH, de Wit H (1997). High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 56: 265-272.
10. Brauer LH, Goudie AJ, de Wit H (1997). Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130: 2-13.
11. Britton DR, Curzon P, Mackenzie RG, Kebabian JW, Williams JE, Kerkman D (1991). Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration. Pharmacol Biochem Behav 39: 911-915.
12. Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J et al (2002). Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci 22: 2977-2988.
13. Cohen MX, Young J, Baek JM, Kessler C, Ranganath C (2005). Individual differences in extraversion and dopamine genetics predict neural reward responses. Brain Res Cogn Brain Res 25: 851-861.
14. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C et al (1996). A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 6: 223-234.
15. Dockstader CL, Rubinstein M, Grandy DK, Low MJ, van der Kooy D (2001). The D2 receptor is critical in mediating opiate motivation only in opiate-dependent and withdrawn mice. Eur J Neurosci 13: 995-1001.
16. Enggasser JL, de Wit H (2001). Haloperidol reduces stimulant and reinforcing effects of ethanol in social drinkers. Alcohol Clin Exp Res 25: 1448-1456.
17. Fletcher PJ (1998). A comparison of the effects of risperidone, raclopride, and ritanserin on intravenous self-administration of d-amphetamine. Pharmacol Biochem Behav 60: 55-60.
18. Grace AA (2000). The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95(Suppl 2): S119-S128.
19. Gunne LM, Anggard E, Jonsson LE (1972). Clinical trials with amphetamine-blocking drugs. Psychiatr Neurol Neurochir 75: 225-226.
20. Haertzen CA (1965). Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis 141: 300-307.
21. Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grusser SM et al (2004). Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 161: 1783-1789.
22. Jonsson L (1972). Pharmacological blockade of amphetamine effects in amphetamine-dependent subjects. Eur J Clin Pharmacol 4: 206-211.
23. Keats AS, Telford J (1964). Narcotic antagonists as analgesics. Clinical aspects. In: Gould RF (ed) Molecular Modification in Drug Design, Advances in Chemistry, Series 45. American Chemical Society: Washington, DC. pp 170-176.
24. Meyer G, Schwertfeger J, Exton MS, Janssen OE, Knapp W, Stadler MA et al (2004). Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology 29: 1272-1280.
25. Morasco BJ, Vom Eigen KA, Petry NM (2006). Severity of gambling is associated with physical and emotional health in urban primary care patients. Gen Hosp Psychiatry 28: 94-100.
26. Nader MA, Czoty PW (2005). PET imaging of dopamine D2 receptors in monkey models of cocaine abuse: genetic predisposition versus environmental modulation. Am J Psychiatry 162: 1473-1482.
27. Noble EP (2000). Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur Psychiatry 15: 79-89.
28. Nordstrom AL, Farde L, Halldin C (1992). Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106: 433-438.
29. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C (2005). Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8: 147-148.
30. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29-39.
31. Scherrer JF, Xian H, Shah KR, Volberg R, Slutske W, Eisen SA (2005). Effect of genes, environment, and lifetime co-occurring disorders on health-related quality of life in problem and pathological gamblers. Arch Gen Psychiatry 62: 677-683.
32. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
33. Self DW, Stein L (1992). Receptor subtypes in opioid and stimulant reward. Pharmacol Toxicol 70: 87-94.
34. Shacham S (1983). A shortened version of the Profile of Mood States. J Pers Assess 47: 305-306.
35. Sherer MA, Kumor KM, Jaffe JH (1989). Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res 27: 117-125.
36. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M et al (2001). Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158: 2015-2021.
37. Volkow ND, Fowler JS, Wang GJ (2004). The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47(Suppl 1): 3-13.
38. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R et al (1990). Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147: 719-724.
39. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A et al (1999). Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156: 1440-1443.
40. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS et al (1996). Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20: 1594-1598.
41. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ et al (2003). Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology 166: 264-270.
42. Volkow ND, Wang GJ, Fowler JS, Thanos PP, Logan J, Gatley SJ et al (2002). Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46: 79-82.
43. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR et al (2006). Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26: 6583-6588.
44. Wachtel SR, Ortengren A, de Wit H (2002). The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 68: 23-33.
45. Wainer H (1991). Adjusting for differential base rates: Lord's paradox again. Psychol Bull 109: 147-151.
46. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ et al (1997). Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16: 174-182.
47. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W et al (2001). Brain dopamine and obesity. Lancet 357: 354-357.
48. Xu M (1998). Unraveling dopamine D3 receptor function in response to psychostimulants using a genetic approach. Ann N Y Acad Sci 844: 27-39.
49. Zack M, Poulos CX (2004). Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology 29: 195-207.